Essential hypertension and chronic viral hepatitis

Digestive and Liver Disease

Volumn 39, Issue 5, 2007, Pages 466-472

  Parrilli, G ^a   Manguso, F ^a   Orsini, L ^a   Coccoli, P ^a   Vecchione, R ^a   Terracciano, L ^a   De Luca, N ^b   Cirillo, N ^a   Abazia, C ^a   Budillon, G ^a   Marchesini, G ^c  

^a Department of Clinical Medicine ^*  (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chronic liver disease; Endothelin 1; Essential hypertension; Mortality; Natural history; Renin Angiotensin system agents

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; INTERFERON;

ADULT; AGE; ARTICLE; BIOCHEMISTRY; CHRONIC HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTE COUNT; VIRUS HEPATITIS;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS, CHRONIC; HEPATITIS, VIRAL, HUMAN; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33947730973     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.01.009     Document Type: Article

References (37)

1. Loyke H.F. The relationship of cirrhosis of the liver to hypertension: a study of 504 cases of cirrhosis of the liver. Am J Med Sci 240 (1955) 627-632
2. Henriksen J.H., and Moller S. Hypertension and liver disease. Curr Hypertens Rep 6 (2004) 453-461
3. Henriksen J.H., Moller S., Schifter S., and Bendtsen F. Increased arterial compliance in decompensated cirrhosis. J Hepatol 31 (1999) 712-718
4. Gentilini P., Romanelli R.G., Laffi G., Barletta G., Del Bene R., Messeri G., et al. Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. J Hepatol 30 (1999) 632-638
5. Llach J., Gines P., Arroyo V., Rimola A., Tito L., Badalamenti S., et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 94 (1988) 482-487
6. Lautt W.W. The 1995 Ciba-Geigy Award Lecture. Intrinsic regulation of hepatic blood flow. Can J Physiol Pharmacol 74 (1996) 223-233
7. Rockey D.C. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology 118 (2000) 1261-1265
8. Rockey D.C. Vascular mediators in the injured liver. Hepatology 37 (2003) 4-12
9. Ramalho L.N., Ramalho F.S., Zucoloto S., Castro-e-Silva Jr. O., Correa F.M., Elias Jr. J., et al. Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. Hepatogastroenterology 49 (2002) 1499-1502
10. Croquet V., Moal F., Veal N., Wang J., Oberti F., Roux J., et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol 37 (2002) 773-780
11. Terui Y., Saito T., Watanabe H., Togashi H., Kawata S., Kamada Y., et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 36 (2002) 1022
12. Rimola A., Londono M.C., Guevara G., Bruguera M., Navasa M., Forns X., et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 78 (2004) 686-691
13. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40 (2004) 1222-1225
14. Rubin E. Alcoholic myopathy in heart and skeletal muscle. N Engl J Med 301 (1979) 28-33
15. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. J Am Med Assoc 289 (2003) 2560-2572
16. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997) 1183-1197
18. Frostegard J., Wu R., Gillis-Haegerstrand C., Lemne C., and de Faire U. Antibodies to endothelial cells in borderline hypertension. Circulation 98 (1998) 1092-1098
19. Ferrari C., and Chisari F.V. Immune mechanisms of viral clearance and disease pathogenesis during viral hepatitis. In: Arias I.M., Boyer J.L., Chisari F.V., Fausto N., Schachter D., and Shafritz D.A. (Eds). The liver: biology and pathobiology (2001), Lippincott Williams & Willkins, Philadelphia 763-782
20. Taddei S., Virdis A., Ghiadoni L., Sudano I., and Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 62 (2002) 265-284
21. Ergul A. Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents. Pharmacotherapy 22 (2002) 54-65
22. Ergul A. Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. Hypertension 36 (2000) 62-67
23. Ersoy Y., Bayraktar N.M., Mizrak B., Ozerol I.H., Gunal S., Aladag M., et al. The level of endothelin-1 and nitric oxide in patients with chronic viral hepatitis B and C correlation with histopathological grading and staging. Hepatol Res 34 (2006) 111-116
24. Uchida Y., and Watanabe M. Plasma endothelin-1 concentrations are elevated in acute hepatitis and liver cirrhosis but not in chronic hepatitis. Gastroenterol Jpn 28 (1993) 666-672
25. Matsumoto H., Uemasu J., Kitano M., and Kawasaki H. Clinical significance of plasma endothelin-1 in patients with chronic liver disease. Dig Dis Sci 39 (1994) 2665-2670
26. Tong Q., and Zeng L. Study on the correlation of plasma NO, ET-1 and ALT in the patients with chronic hepatitis and cirrhosis. J Tongji Med Univ 20 (2000) 203-204
27. Pata C., Yazar A., Altintas E., Polat G., Aydin O., Tiftik N., et al. Serum levels of intercellular adhesion molecule-1 and nitric oxide in patients with chronic hepatitis related to hepatitis C virus: connection fibrosis. Hepatogastroenterology 50 (2003) 794-797
28. Moussa Y.I., Plevris J.N., and Hayes P.C. Plasma nitrites/nitrates in HCV infection and hepatocellular carcinoma. Eur J Gastroenterol Hepatol 12 (2000) 159-163
29. Laviades C., Varo N., Fernandez J., Mayor G., Gil M.J., Monreal I., et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98 (1998) 535-540
30. Yoo K.H., Thornhill B.A., Wolstenholme J.T., and Chevalier R.L. Tissue-specific regulation of growth factors and clusterin by angiotensin II. Am J Hypertens 11 (1998) 715-722
31. Tong M.J., el-Farra N.S., Reikes A.R., and Co R.L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332 (1995) 1463-1466
32. Poynard T., Ratziu V., Charlotte F., Goodman R., McHutchison J., Albrecht J., et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34 (2001) 730-739
33. Kobayashi M., Ikeda K., Hosaka T., Sezaki H., Sameya T., Akuta N., et al. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 78 (2006) 459-465
34. Hui J.M., Kench J., Farrel G.C., Lin R., Samarasinghe D., Liddle C., et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 17 (2002) 873-881
35. Yano M., Kumada H., Kage M., Ikeda K., Shimamatsu K., Inoue O., et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 23 (1996) 1334-1340
36. Ghany M.G., Kleiner D.E., Alter H.J., Doo E., Herion D.W., and Khokar F. Progression of fibrosis in early stages of chronic hepatitis C. Hepatology 32 (2000) 496
37. Seljeflot I., Arnesen H., Andersen P., Aspelin T., and Kierulf P. Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men. J Cardiovasc Pharmacol 34 (1999) 584-588